ArticlePloS one2026
Rehospitalization due to COVID-19 reinfection in Rio de Janeiro, 2020-2022: Associations with vaccination status, sociodemographic and clinical factors.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic posed significant challenges, including rehospitalization of patients due to SARS-CoV-2 reinfection, particularly in the context of variants of concern and Brazil's COVID-19 vaccination campaign. This study aimed to estimate the rate of rehospitalizations due to reinfection in the municipality of Rio de Janeiro (2020-2022), assess the impact of individual vaccination status, and identify factors associated with this outcome. Cohort study including individuals aged 18 years or older who were hospitalized with Severe Acute Respiratory Illness (SARI) resulting from SARS-CoV-2 infection in Rio de Janeiro. Data from four administrative databases (SIPNI, e-SUS Notifica, SIVEP-Gripe, and SIM) were integrated through record linkage. Rehospitalizations due to reinfection were defined as those occurring ≥90 days after the initial hospitalization. Annual rehospitalization rates were calculated per 100 person-years. The analysis included demographics, hospital discharge disposition, and vaccination-related variables. Cox proportional hazards models with deaths considered as competing risks were used. Of the 59,001 individuals included, 1,957 (3.3%) experienced rehospitalization. The main finding was that a complete vaccination regimen with a booster (≥3 doses) was associated with a 39% reduction in the risk of rehospitalization (sHR: 0.61; 95% CI: 0.52-0.73), while older age, multimorbidity, and Black race/skin color emerged as significant risk factors. Full vaccination with booster doses offered protection against COVID-19-related rehospitalization; however, racial inequities, advanced age, and comorbidities remain important risk factors. Public health policies that expand periodic booster vaccination, strengthen health education, and address social vulnerabilities are urgently needed as a fundamental strategy for preventing future pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.